222 related articles for article (PubMed ID: 27383411)
41. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
42. von Hippel-Lindau exonic methylation analysis using MALDI-TOF mass spectrometry.
Lian F; Sreedharan S; Arnold RS; Master VA; Ogan K; Pattaras JG; Roberts DL; Petros JA
J Urol; 2014 Nov; 192(5):1528-33. PubMed ID: 24704013
[TBL] [Abstract][Full Text] [Related]
43. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
Banks RE; Tirukonda P; Taylor C; Hornigold N; Astuti D; Cohen D; Maher ER; Stanley AJ; Harnden P; Joyce A; Knowles M; Selby PJ
Cancer Res; 2006 Feb; 66(4):2000-11. PubMed ID: 16488999
[TBL] [Abstract][Full Text] [Related]
44. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.
Inoue H; Nonomura N; Kojima Y; Shiba M; Oka D; Arai Y; Nakayama M; Takayama H; Nishimura K; Mori H; Okuyama A
Nephrol Dial Transplant; 2007 Jul; 22(7):2052-5. PubMed ID: 17438007
[TBL] [Abstract][Full Text] [Related]
45. [Inactivation of the VHL gene in sporadic clear cell renal cancer].
Mikhaĭlenko DS; Kurynin RB; Popov AM; Kariakin OB; Enikeev ME; Aliaev IuG; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2008; 42(1):71-7. PubMed ID: 18389622
[TBL] [Abstract][Full Text] [Related]
46. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
47. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
[TBL] [Abstract][Full Text] [Related]
48. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma.
Brauch H; Weirich G; Hornauer MA; Störkel S; Wöhl T; Brüning T
J Natl Cancer Inst; 1999 May; 91(10):854-61. PubMed ID: 10340905
[TBL] [Abstract][Full Text] [Related]
49. Renal cell carcinoma with areas mimicking renal angiomyoadenomatous tumor/clear cell papillary renal cell carcinoma.
Petersson F; Grossmann P; Hora M; Sperga M; Montiel DP; Martinek P; Gutierrez ME; Bulimbasic S; Michal M; Branzovsky J; Hes O
Hum Pathol; 2013 Jul; 44(7):1412-20. PubMed ID: 23434146
[TBL] [Abstract][Full Text] [Related]
50. Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated ccRCC.
Li L; Bao H; Xu Y; Yang W; Zhang Z; Ma K; Zhang K; Zhou J; Gong Y; Ci W; Gong K
Mol Diagn Ther; 2023 Nov; 27(6):741-752. PubMed ID: 37587253
[TBL] [Abstract][Full Text] [Related]
51. [Tumor size and DNA ploidy changes in renal cell carcinomas--flow cytometric analysis of DNA content in renal cell carcinomas associated with von Hippel-Lindau disease].
Nagamori S; Shinohara N; Kashiwagi A; Togashi M; Seki H; Toyota K; Harabayashi T; Nonomura K; Koyanagi T
Nihon Hinyokika Gakkai Zasshi; 1996 Apr; 87(4):754-9. PubMed ID: 8691697
[TBL] [Abstract][Full Text] [Related]
52. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients.
Cascón A; Escobar B; Montero-Conde C; Rodríguez-Antona C; Ruiz-Llorente S; Osorio A; Mercadillo F; Letón R; Campos JM; García-Sagredo JM; Benítez J; Malumbres M; Robledo M
Hum Mutat; 2007 Jun; 28(6):613-21. PubMed ID: 17311301
[TBL] [Abstract][Full Text] [Related]
53. Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma.
Schouten LJ; van Dijk BA; Oosterwijk E; van Engeland M; Hulsbergen-van de Kaa CA; Kiemeney LA; Goldbohm RA; Kester A; de Vogel S; Schalken JA; van den Brandt PA
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3543-50. PubMed ID: 19064569
[TBL] [Abstract][Full Text] [Related]
54. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
[TBL] [Abstract][Full Text] [Related]
55. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3.
Malinoc A; Sullivan M; Wiech T; Schmid KW; Jilg C; Straeter J; Deger S; Hoffmann MM; Bosse A; Rasp G; Eng C; Neumann HP
Endocr Relat Cancer; 2012 Jun; 19(3):283-90. PubMed ID: 22351710
[TBL] [Abstract][Full Text] [Related]
56. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
Shuin T; Kondo K; Torigoe S; Kishida T; Kubota Y; Hosaka M; Nagashima Y; Kitamura H; Latif F; Zbar B
Cancer Res; 1994 Jun; 54(11):2852-5. PubMed ID: 8187067
[TBL] [Abstract][Full Text] [Related]
57. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
58. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
Kroeger N; Klatte T; Chamie K; Rao PN; Birkhäuser FD; Sonn GA; Riss J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
Cancer; 2013 Apr; 119(8):1547-54. PubMed ID: 23335244
[TBL] [Abstract][Full Text] [Related]
59. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.
Gallou C; Joly D; Méjean A; Staroz F; Martin N; Tarlet G; Orfanelli MT; Bouvier R; Droz D; Chrétien Y; Maréchal JM; Richard S; Junien C; Béroud C
Hum Mutat; 1999; 13(6):464-75. PubMed ID: 10408776
[TBL] [Abstract][Full Text] [Related]
60. Mutations of the VHL tumour suppressor gene in renal carcinoma.
Gnarra JR; Tory K; Weng Y; Schmidt L; Wei MH; Li H; Latif F; Liu S; Chen F; Duh FM
Nat Genet; 1994 May; 7(1):85-90. PubMed ID: 7915601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
